Compare ImmunityBio Inc. Common Stock (IBRX) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Immunovant Inc. Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $10.3 (market cap $10.51B), while Immunovant Inc. Common Stock trades at $30.3 (market cap $6.25B). The key difference: ImmunityBio Inc. Common Stock is the larger of the two by market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Immunovant Inc. Common Stock for 0 Days on average.
| IBRX | IMVT | |
|---|---|---|
Market Cap | $10.51B | $6.25B |
Volume | 10,445,785 | 1,755,411 |
Sector | Health | Health |
52-Week High | $11.55 | $44.96 |
52-Week Low | $1.98 | $17.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.97B | $5.35B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
